Brensocatib

Brensocatib
Clinical data
Other names	AZD7986; INS1007
Identifiers
	IUPAC name (2S)-N-[(1S)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide;
CAS Number	1802148-05-5;
PubChem CID	118253852;
IUPHAR/BPS	9412;
DrugBank	DB15638;
ChemSpider	67896269;
UNII	25CG88L0BB;
KEGG	D12120;
ChEMBL	ChEMBL3900409;
Chemical and physical data
Formula	C23H24N4O4
Molar mass	420.469 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C2=C(C=CC(=C2)C3=CC=C(C=C3)C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)OC1=O;
	InChI InChI=1S/C23H24N4O4/c1-27-19-12-17(7-8-20(19)31-23(27)29)16-5-3-15(4-6-16)11-18(13-24)26-22(28)21-14-25-9-2-10-30-21/h3-8,12,18,21,25H,2,9-11,14H2,1H3,(H,26,28)/t18-,21-/m0/s1; Key:AEXFXNFMSAAELR-RXVVDRJESA-N;

Brensocatib is an investigational new drug that is being evaluated to treat bronchiectasis.^[1] It is a dipeptidyl-peptidase I (also known as cathepsin C) inhibitor.^[2]

A phase 3 clinical trial, known as the ASPEN trial, was conducted to evaluate the safety and efficacy of brensocatib in patients with non-cystic fibrosis bronchiectasis.^[3]

References

^ "Brensocatib - Insmed". AdisInsight. Springer Nature Switzerland AG.
^ Chalmers JD, Usansky H, Rubino CM, Teper A, Fernandez C, Zou J, et al. (October 2022). "Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis". Clinical Pharmacokinetics. 61 (10): 1457–1469. doi:10.1007/s40262-022-01147-w. PMC 9553789. PMID 35976570.
^ Chalmers JD, Burgel PR, Daley CL, De Soyza A, Haworth CS, Mauger D, et al. (April 2025). "Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis". The New England Journal of Medicine. 392 (16): 1569–1581. doi:10.1056/NEJMoa2411664. PMID 40267423.

[1] "Brensocatib - Insmed". AdisInsight. Springer Nature Switzerland AG.

[Chalmers_2022-2] Chalmers JD, Usansky H, Rubino CM, Teper A, Fernandez C, Zou J, et al. (October 2022). "Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis". Clinical Pharmacokinetics. 61 (10): 1457–1469. doi:10.1007/s40262-022-01147-w. PMC 9553789. PMID 35976570.

[3] Chalmers JD, Burgel PR, Daley CL, De Soyza A, Haworth CS, Mauger D, et al. (April 2025). "Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis". The New England Journal of Medicine. 392 (16): 1569–1581. doi:10.1056/NEJMoa2411664. PMID 40267423.

[1]

[2]

[3]